Literature DB >> 34385341

Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.

Michael S Hofman1.   

Abstract

Entities:  

Keywords:  Genitourinary; Oncology: GU; PSMA; Radionuclide Therapy; lutetium-177; prostate cancer; theranostics

Year:  2021        PMID： 34385341      PMCID： PMC8612181          DOI： 10.2967/jnumed.121.262890

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  12 in total

1.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Clemens Kratochwil; Martina Benesova; Matthias Eder; Oliver C Neels; Michael Eisenhut; Wolfgang Kübler; Tim Holland-Letz; Frederik L Giesel; Walter Mier; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

Review 2.  Nuclear Medicine and Wall Street: An Evolving Relationship.

Authors:  Mike Sherman; Rachel Levine
Journal:  J Nucl Med       Date:  2019-09       Impact factor: 10.057

3.  UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).

Authors:  Nattakorn Dhiantravan; Louise Emmett; Anthony M Joshua; David A Pattison; Roslyn J Francis; Scott Williams; Shahneen Sandhu; Ian D Davis; Ian Vela; Nitika Neha; Mathias Bressel; Declan G Murphy; Michael S Hofman; Arun A Azad
Journal:  BJU Int       Date:  2021-03-07       Impact factor: 5.588

4.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

Authors:  H Liu; P Moy; S Kim; Y Xia; A Rajasekaran; V Navarro; B Knudsen; N H Bander
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

5.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Authors:  Ronald de Wit; Johann de Bono; Cora N Sternberg; Karim Fizazi; Bertrand Tombal; Christian Wülfing; Gero Kramer; Jean-Christophe Eymard; Aristotelis Bamias; Joan Carles; Roberto Iacovelli; Bohuslav Melichar; Ásgerður Sverrisdóttir; Christine Theodore; Susan Feyerabend; Carole Helissey; Ayse Ozatilgan; Christine Geffriaud-Ricouard; Daniel Castellano
Journal:  N Engl J Med       Date:  2019-09-30       Impact factor: 91.245

6.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

Authors:  R S Israeli; C T Powell; W R Fair; W D Heston
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

7.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Authors:  John Violet; Price Jackson; Justin Ferdinandus; Shahneen Sandhu; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Sue Ping Thang; Peter Eu; Mark Scalzo; Declan Murphy; Scott Williams; Rodney J Hicks; Michael S Hofman
Journal:  J Nucl Med       Date:  2018-10-05       Impact factor: 10.057

8.  Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Authors:  John Violet; Shahneen Sandhu; Amir Iravani; Justin Ferdinandus; Sue-Ping Thang; Grace Kong; Aravind Ravi Kumar; Tim Akhurst; David A Pattison; Alexis Beaulieu; Jennifer Mooi; Ben Tran; Christina Guo; Victor Kalff; Declan G Murphy; Price Jackson; Peter Eu; Mark Scalzo; Scott Williams; Rodney J Hicks; Michael S Hofman
Journal:  J Nucl Med       Date:  2019-11-15       Impact factor: 11.082

9.  Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

Authors:  Nattakorn Dhiantravan; John Violet; Renu Eapen; Omar Alghazo; Mark Scalzo; Price Jackson; Simon P Keam; Catherine Mitchell; Paul J Neeson; Shahneen Sandhu; Scott G Williams; Daniel Moon; Nathan Lawrentschuk; Arun Azad; Michael S Hofman; Declan G Murphy
Journal:  Eur Urol Focus       Date:  2020-11-07

10.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245
View more
  1 in total

Review 1.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.